Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Botensilimab ± Balstilimab in Patients with Advanced Cutaneous Melanoma Refractory/Resistant to Anti–PD-(L)1 ± CTLA-4: A Phase 2 Trial
May 31, 2026
,
Atkins, M. et al.
ASCO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Botensilimab ± Balstilimab in Patients with Advanced Cutaneous Melanoma Refractory/Resistant to Anti–PD-(L)1 ± CTLA-4: A Phase 2 Trial
ASCO
American Society of Clinical Oncology (ASCO)
May 31, 2026
,
Atkins, M. et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Artificial Intelligence (AI) foundation model as a predictor of efficacy of next generation checkpoint inhibition with botensilimab (BOT) + balstilimab (BAL) in solid tumors using pretreatment H&E images
ASCO
American Society of Clinical Oncology (ASCO)
May 31, 2026
,
Dalton R., et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
The CO.33/BATTMAN trial: A phase 3 randomized study of botensilimab + balstilimab versus best supportive care in chemorefractory unresectable colorectal adenocarcinoma that is not dMMR/MSI-H
ASCO
American Society for Clinical Oncology (ASCO)
May 30, 2026
,
Loree et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Preliminary Results of First-line Botensilimab and Balstilimab OPtimization in Microsatellite Stable COlorectal Cancer without liver, bone, or brain metastasis
AACR
American Association for Cancer Research (AACR)
April 21, 2026
,
DeVito, N. et al.